GlassScriptPhysician profile
Irene H Chen
NPI 1487317442
$5,006.67
in general payments reported to CMS, 2019-2025
27 companies · $1,928 in 2025
The $1,928 reported for 2025 was more than what 95% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $1,460 · 2023: $1,159 · 2024: $335 · 2025: $1,928.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,354 · Travel and Lodging: $967 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,354.18 |
| Travel and Lodging | $966.76 |
| Education | $100.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $1,283.96 | 2022-2025 | Synergy Ablation System, Epi-Sense Guided Coagulation System With Visitrax, Atriclip Laa Exclusion System |
| Edwards Lifesciences Corporation | $588.97 | 2023-2025 | Evoque, Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Boston Scientific Corporation | $521.82 | 2021-2025 | Watchman Access System, Watchman Flx, Emblem Mri S-Icd |
| Novartis Pharmaceuticals Corporation | $307.92 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $222.40 | 2022-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $213.96 | 2022-2023 | Farxiga |
| Neurocrine Biosciences, INC. | $173.88 | 2022 | |
| Alnylam Pharmaceuticals INC. | $143.72 | 2025 | Onpattro |
| Kiniksa Pharmaceuticals, LTD. | $138.58 | 2022-2023 | Arcalyst |
| Silk Road Medical, INC. | $133.34 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Actelion Pharmaceuticals US, INC. | $125.00 | 2022 | |
| Medtronic, INC. | $124.70 | 2023-2024 | Intellis Adaptivestim, Micra |
| Abbvie INC. | $123.79 | 2023 | |
| Melinta Therapeutics, LLC | $121.95 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $120.69 | 2024 | Uzedy |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $105.53 | 2022-2023 | |
| United Therapeutics Corporation | $97.52 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $96.96 | 2022 | |
| Merck Sharp & Dohme LLC | $69.87 | 2022 | |
| Inspire Medical Systems, INC. | $54.08 | 2024 | Inspire |
| Glaxosmithkline, LLC. | $48.97 | 2023 | Trelegy Ellipta |
| Amgen INC. | $45.48 | 2022-2023 | Repatha |
| Abiomed | $44.05 | 2025 | |
| Impulse Dynamics (USA) INC. | $28.10 | 2023 | Optimizer |
| Kestra Medical Technology Services, INC. | $25.93 | 2022 | |
| Janssen Pharmaceuticals, INC | $23.72 | 2023 | Xarelto |
| Amarin Pharma, INC. | $21.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irene Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.